TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00806416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: alendronate
Description: A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
Study: NCT01464528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronan
Description: single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
Study: NCT05404516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3.
Study: NCT00806416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: alendronate
Description: A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: cholecalciferol (Vitamin D)
Description: A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: cholecalciferol (Vitamin D)
Description: A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
Study: NCT01906801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Study: NCT02203591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep C
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep CH
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study: NCT05210036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Therapy (US)
Description: All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Laser Therapy (HILT)
Description: All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.
Study: NCT02290587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI - Clinical and cognitive evaluation
Description: Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI - Clinical and cognitive evaluation
Description: Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention
Study: NCT01906801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Diacerein)
Description: Sugar pill manufactured to mimic Diacerein 50 mg tablet
Study: NCT02290587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT03428776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compliance-linked incentives
Description: Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent Compliance-linked incentives
Description: Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Record keeping
Description: Electronic immunization records on cloud-based software platform and use of biometric identification
Study: NCT00861419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 125 mg PO (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 75 mg PO (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 10 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 10 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 10 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg PO (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg PO (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3 mg/kg IV (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3 mg/kg IV (QW)
Study: NCT04707235

Intervention type: DRUG
Intervention: Hydroxycarbamide
Description: Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
Study: NCT04104139

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT00793442

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection and Assays
Description: The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection and Assays
Description: The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
Study: NCT04034589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with fulvestrant
Description: Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
Study: NCT02550652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil/Mycophenolic Acid
Description: MMF/MPA will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil/Mycophenolic Acid
Description: MMF/MPA will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as per schedule specified in the respective arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone IV will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone IV will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered as per schedule specified in the respective arm.
Study: NCT03079804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental MWM
Description: Mobilization with Movement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental MWM
Description: Mobilization with Movement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental MWM
Description: Mobilization with Movement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Thrust
Description: Mobilization grade 5 (Thrust)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Thrust
Description: Mobilization grade 5 (Thrust)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Thrust
Description: Mobilization grade 5 (Thrust)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Procedures similar to Experimental MWM group, but without aplly any force

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Procedures similar to Experimental MWM group, but without aplly any force

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedures similar to Experimental MWM group, but without aplly any force
Study: NCT04298528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5mg 2 times a day for 30 days after total knee replacement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times a day for 30 days after total knee replacement
Study: NCT01511887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ibuprofen
Description: 10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
Study: NCT03970109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637
Description: 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637
Description: 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study: NCT02442830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Video Capsule Endoscopy
Description: The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue.
Study: NCT01412775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short-term group intervention program
Description: The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration.
Study: NCT04118322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy (peppermint oil)
Description: The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)
Study: NCT02682420

Intervention type: DEVICE
Group type: OTHER
Intervention: everlinQ endoAVF System
Study: NCT03273036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Triamcinolone acetate 1 cc
Description: 40 mg Triamcinolone acetate 1 cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: no injected agent
Study: NCT02877550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: p.o. once daily according to dose level (DL) or MTD
Study: NCT01252459

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
Study: NCT03747081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
Study: NCT00983814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa+Carbidopa
Description: 3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Droxidopa+Carbidopa
Description: 3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
Study: NCT02541240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience Curriculum
Description: The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
Study: NCT04891679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral misoprostol solution (OMS)
Description: Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral misoprostol solution (OMS)
Description: Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.
Study: NCT01891734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy plus Moving Forward
Description: All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
Study: NCT00220818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
Study: NCT01312467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Study: NCT04431232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Band Ligation
Description: Band ligation of the gastric body for weight loss